Aktienanalyse zu aTyr Pharma Inc (ATYR)ATYRaTyr Pharma Inc

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

aTyr Pharma Inc is a good buy right now due to its recent improvements in financial management and a significant upgrade from analysts. The stock currently trades at $0.54, with a projected price target of $3.50, indicating a potential upside of over 548%. Furthermore, the company has narrowed its net loss to $10.31 million in Q2 2026, down from $19.53 million the previous year, showing progress in cost management. However, investors should be aware of the risk of needing additional financing for ongoing clinical trials, which could impact share price.